Intuitive Surgical reported second-quarter 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. The company's share price is down 28.6% year to date, with a one-year total shareholder return decline of 16.1%, though the recent seven-day return of 8.95% and three-year total shareholder return of 30.9% suggest longer-term holders have still seen gains. A community narrative pegs Intuitive Surgical's fair value at $630.48 versus the last close of $401.23, implying the stock is 36.4% undervalued, but the current P/E of 45.2x is well above the U.S. Medical Equipment industry at 26.3x and the peer average at 28.8x.
Intuitive Surgical IncRising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms, plus slower US procedure growth.
Johnson & JohnsonMentioned as a competitor applying pressure on Intuitive Surgical, but no direct impact on J&J stated.
